Secukinumab-human interleukin-IL-17A antagonist for the treatment of moderate to severe plaque psoriasis.

Date- 1/21/2015

The U.S. Food and Drug Administration  approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.

—————————–Mechanism of action————————————-

  • Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.
  • It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line.
  • It has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.
  • IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
  • Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

 ———————————DOSAGE AND ADMINISTRATION——————————–

  • Recommended dose is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable.
  • COSENTYX injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. COSENTYX is supplied in a single-use Sensoready pen with a 27 gauge fixed ½ inch needle, or a single-use prefilled syringe with a 27 gauge fixed ½ inch needle. The removable cap of the COSENTYX Sensoready pen or prefilled syringe contains natural rubber latex.

————————-WARNINGS AND PRECAUTIONS————————–

 Infections

Tuberculosis (TB)

Crohn’s Disease

Hypersensitivity Reactions

 ———————————ADVERSE REACTIONS———————————————

Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Cosentyx is marketed by East Hanover, New Jersey-based Novartis Pharmaceuticals Corporation.

For more details Click here to visit FDA site.